S2-E7.1 - The Newer Diabetes Drugs and NASH: Modes of Action

Send us a text

Jörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH.

The group considers scientific issues surrounding the newer diabetes drugs. First, Jörn Schattenberg presented mode-of-action and research data on the two classes of drugs. After this, Wayne Eskridge asked questions from the patient perspective, Louise Campbell explores issues from a holistic perspective and Roger Green raised data points and concepts that arose in earlier episodes of the podcast.